TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Wednesday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Up 2.2 %

Shares of NASDAQ TXMD opened at $1.83 on Wednesday. The stock has a 50 day simple moving average of $1.91 and a 200-day simple moving average of $2.10. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.31 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC purchased a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned approximately 2.57% of TherapeuticsMD as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.